Table 2 Multiple Cox regression model.

From: NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors

 

Unadjusted

Adjusted

Variable

HR

95% CI

P

HR

95% CI

P

Biomarker score, 3

1

  

1

  

 2

2.435

1.070–5.540

0.034

2.211

0.951–5.138

0.065

 1

3.971

1.763–8.943

0.001

5.560

2.359–13.101

<0.001

PDL1 status, <50%

1

  

1

  

 ≥50%

1.325

0.696–2.523

0.391

2.791

1.206–6.458

0.017

Histology, adenocarcinoma

1

  

1

  

 Othera

1.621

0.950–2.766

0.077

1.991

1.034–3.832

0.039

Performance status, 0

1

  

1

  

 1–2

1.833

1.087–3.091

0.023

2.219

1.230–4.006

0.008

  1. Multiple Cox regression analysis performed on 71 patients with 55 deaths occurring during the observation time. The group with biomarker score 1 had an abnormal level of IFNγ (<250 pg/ml) and detectable methylated HOXA9, group 2 had either abnormal levels of IFNγ and undetectable methylated HOXA9 or normal levels of IFNγ and detectable methylated HOXA9, and group 3 had normal levels of IFNγ (≥250 pg/ml) and undetectable methylated HOXA9. Unadjusted values represent simple Cox regression analyses. Adjusted values represent the full multiple Cox regression model.
  2. aThis category comprises primarily squamous cell carcinoma. Please refer to footnote of Table 1 for the full list of other histologic types included.
Back to article page